{
  "id": "62008577c9dfcb9c0900001f",
  "type": "summary",
  "question": "What is the use of the ATRIA score?",
  "ideal_answer": "ATRIA score determines bleeding risk for patients on warfarin.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/31800901",
    "http://www.ncbi.nlm.nih.gov/pubmed/29030869",
    "http://www.ncbi.nlm.nih.gov/pubmed/28363682",
    "http://www.ncbi.nlm.nih.gov/pubmed/24991318",
    "http://www.ncbi.nlm.nih.gov/pubmed/29274754",
    "http://www.ncbi.nlm.nih.gov/pubmed/29560065",
    "http://www.ncbi.nlm.nih.gov/pubmed/33550837"
  ],
  "snippets": [
    {
      "text": "Many parameters included in the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) and CHA2DS2-VASc (congestive heart failure, hypertension, age \u226575 years, diabetes mellitus, stroke, vascular disease, age 65-74 years, sex category) scores also predict coronary artery disease (CAD). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33550837",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The HAS-BLED, ATRIA, and ORBIT Bleeding Scores in Atrial Fibrillation Patients Using Non-Vitamin K Antagonist Oral Anticoagulants.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29274754",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "METHODS: Using the Danish registries, we evaluated and compared the risk classification properties of the Hypertension, Age, Stroke, Bleeding tendency/predisposition, Labile international normalized ratios, Elderly age/frailty, Drugs such as concomitant aspirin/nonsteroidal anti-inflammatory drugs or alcohol excess (HAS-BLED), Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA), and Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT) scores for predicting major bleeding in 57,930 atrial fibrillation patients (44.6% female; mean age 73.5 years, standard deviation 11.4 years; mean CHA2DS2-VASc score 3.2, standard deviation 1.8).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29274754",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "All the BRSs show a satisfactory calibration for major and CRB events. Among these BRSs, only HEMORR2 HAGES (C-statistic\u00a0=\u00a00.71, 95% CI 0.60-0.82, P\u00a0<\u00a0.001) and ATRIA score (C-statistic\u00a0=\u00a00.70, 95% CI 0.58-0.82, P\u00a0<\u00a0.001) show acceptable discrimination performance for major bleeding events. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29030869",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Patients were then sorted into two groups at non-low and low risk of bleeding, as defined by an ATRIA score >3 and \u22643 respectively, and compared regarding major adverse cardiac and vascular events (MACVE) and bleeding.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28363682",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Methods: This prospective study included non-anticoagulated adults at high risk for ischemic stroke (ATRIA score \u22657) who received emergency AF/FL care and were discharged home from seven community EDs between May 2011 and August 2012. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29560065",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "viduals with moderate-to-high stroke risk per CHADS2 but not at high bleeding risk per ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) bleeding risk score were evaluated for warfarin use, as identified by the presence of \u22651 warfarin prescription claims within 12 months after the index diagnosis. War",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24991318",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: The AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) risk score used to detect the thromboembolic and hemorrhagic risk in atrial fibrillation patients has been shown recently to predict poor clinical outcomes in patients with acute myocardial infarction (ACS), regardless of having atrial fibrillat",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31800901",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}